PowerLook Tomo Detection Version 2.0 Submitted for FDA Approval

Conference call today at 4:30 p.m. ET

NASHUA, N.H. (August 14, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology

company providing innovative cancer detection and therapy solutions, today reported financial results for the three and six months ended June 30, 2018.

Second Quarter 2018 Highlights:

  • Total revenue of $6.2 million, down 4% year-over-year
  • Gross profit of $4.8 million, or 78%
  • GAAP Net Loss of ($1.0) million, or ($0.06) per share
  • Non-GAAP Adjusted EBITDA loss of ($0.3) million
  • Submitted PowerLook Tomo Detection Version 2.0 for FDA approval in May

View Webcast

Full Results